指南与共识治疗药物监测与药物基因组学药物不良反应与药物警戒

CPIC指南:SLCO1B1、ABCG2和CYP2C9基因型与他汀相关肌肉骨骼症状

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
指南 / 共识 · Clin Pharmacol Ther · 2022-03-11

CPIC发布指南,基于SLCO1B1、ABCG2和CYP2C9基因型为他汀相关肌肉骨骼症状(SAMS)提供治疗推荐。指南总结文献支持这些基因变异影响他汀全身暴露并增加SAMS风险,旨在改善他汀治疗的安全性、依从性和有效性,并取代2012和2014年CPIC指南。

要点

  • SLCO1B1、ABCG2和CYP2C9基因变异影响他汀全身暴露,增加SAMS风险。
  • 指南基于上述基因型提供他汀治疗推荐,以改善安全性和依从性。
  • 本指南取代2012和2014年CPIC关于SLCO1B1和辛伐他汀诱导肌病的指南。

核心结论

  • SLCO1B1、ABCG2和CYP2C9基因变异改变他汀全身暴露,增加SAMS风险,指南据此提供治疗推荐。

研究设计与样本

  • CPIC制定的指南,总结文献支持基因与SAMS关联并提供治疗推荐,取代2012和2014年CPIC指南。

主要发现

  • SLCO1B1编码的转运体促进所有他汀的肝脏摄取。
  • ABCG2编码的外排转运体调节瑞舒伐他汀的吸收和处置。
  • CYP2C9编码的I相代谢酶负责部分他汀的氧化。
  • 上述基因变异改变辛伐他汀、瑞舒伐他汀、普伐他汀、匹伐他汀、阿托伐他汀、氟伐他汀、洛伐他汀的全身暴露。
  • 基因变异导致的全身暴露改变可增加SAMS风险。

临床怎么用

  • 根据SLCO1B1、ABCG2和CYP2C9基因型选择他汀或调整剂量,以改善安全性、依从性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Statins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP-C) that facilitates the hepatic uptake of all statins. ABCG2 encodes an efflux transporter (BCRP) that modulates the absorption and disposition of rosuvastatin. CYP2C9 encodes a phase I drug metabolizing enzyme responsible for the oxidation of some statins. Genetic variation in each of these genes alters systemic exposure to statins (i.e., simvastatin, rosuvastatin, pravastatin, pitavastatin, atorvastatin, fluvastatin, lovastatin), which can increase the risk for SAMS. We summarize the literature supporting these associations and provide therapeutic recommendations for statins based on SLCO1B1, ABCG2, and CYP2C9 genotype with the goal of improving the overall safety, adherence, and effectiveness of statin therapy. This document replaces the 2012 and 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for SLCO1B1 and simvastatin-induced myopathy.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022. PMID: 35152405. doi:10.1002/cpt.2557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。